2025 年 3 月 28 日，济民健康管理股份有限公司（以下简称"公司"）以现 场结合通讯方式召开了第五届董事会第十七次会议，审议并一致通过了公司《关 于解聘公司副总裁的议案》。 证券代码：603222 证券简称：济民健康 公告编号：2025-007 济民健康管理股份有限公司 关于解聘公司副总裁的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 何清红女士涉嫌伪造公司印章罪，现已被台州市公安局黄岩分局立案侦查。 董事会同意解聘何清红女士担任的副总裁职务，解聘自本次董事会审议通过之日 起生效。解聘后何清红女士不再担任公司任何职务，此次解聘事项不会对公司正 常经营管理造成影响。 截至本公告披露日，何清红女士未持有公司股份，不存在应当履行而未履 行的承诺事项。 特此公告。 济民健康管理股份有限公司董事会 2025 年 3 月 29 日 ...

证券代码：603222 证券简称：济民健康 公告编号：2025-008 济民健康管理股份有限公司 关于以集中竞价交易方式回购股份的预案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于 1 亿元（含）且不超过 2 亿元（含）； ● 回购股份资金来源：自有资金及金融机构借款； ● 回购股份用途：本次回购股份将用于员工持股计划或股权激励，公司将在发 布回购结果暨股份变动公告后 36 个月内完成转让。若公司未能或未能全部实施 上述用途，未使用部分将依法予以注销； ● 回购股份价格：不超过人民币 10.00 元/股（含），该回购价格上限不高于董 事会通过回购决议前 30 个交易日公司股票交易均价的 150%； ● 回购股份方式：以集中竞价交易方式回购公司股份； ● 回购股份期限：自公司董事会审议通过回购方案之日起不超过 12 个月； ● 相关股东是否存在减持计划：截至审议本次回购股份方案的董事会决议日， 公司控股股东、实际控制人、董监高在未来 3 个月、未来 6 个月不存在减持公司 股份的计 ...

Core Viewpoint - The company, Jimin Health Management Co., Ltd., is facing a serious issue involving the alleged forgery of company seals by its vice president, He Qinghong, and her team, which has led to legal actions and potential financial liabilities [1][2]. Group 1: Incident Overview - Jimin Health reported that its vice president, He Qinghong, and her team forged company seals and used them to sign unauthorized agreements with distributors [1][2]. - The company received lawyer letters from distributors claiming they had signed supplementary agreements requiring the company to fulfill return and refund obligations [2]. - The company has initiated an investigation and reported the incident to the local police, receiving a case notification [1][2]. Group 2: Financial Impact - In 2023 and 2024, He Qinghong's team achieved sales of approximately 117.199 million yuan, but the company is currently unaware of the distributors' inventory levels, posing a risk of lawsuits for refunds [3]. - The company has reported a significant decline in sales volume for safety syringes, down 61.32% year-on-year, while sales of pre-filled catheter flushing devices increased by 807.08% [5]. - Jimin Health is expected to report a net loss of 10 to 15 million yuan for 2024, which would be an improvement compared to the previous year [6][7]. Group 3: Company Response and Future Actions - The company is cooperating with law enforcement and has taken steps to terminate He Qinghong's position and restructure her sales team [4]. - Jimin Health plans to conduct a thorough review of the business operations related to the incident and engage with external legal teams to prepare for potential litigation [4]. - The company emphasizes that its production and operations remain normal and that it will comply with legal disclosure requirements as the case progresses [4].

Core Viewpoint - The article discusses the legal issues faced by Jimin Health due to the alleged criminal activities of its Vice President, He Qinghong, who is accused of forging company seals and signing unauthorized agreements with distributors, leading to potential financial liabilities for the company [3][8][11]. Group 1: Incident Overview - Jimin Health announced that its Vice President, He Qinghong, and her team are under investigation for allegedly forging company seals and committing fraud [3][4]. - The company reported receiving legal letters from distributors claiming rights under supplementary agreements that were signed using the forged seals, demanding refunds and compensation [5][10]. Group 2: Legal Actions and Company Response - Following the discovery of the fraudulent activities, Jimin Health reported the matter to the police, which has since opened a criminal investigation [8][11]. - The company plans to take several measures, including cooperating with law enforcement, pursuing recovery of losses, and restructuring its sales team to ensure business continuity [11][12]. Group 3: Financial Implications - He Qinghong's team reportedly generated sales of approximately 117 million yuan in 2023 and 2024, but the company is currently unable to ascertain the inventory levels held by distributors, posing a risk of lawsuits for refunds [10]. - The company has stated that the ongoing investigation has not affected its normal production and operations [12].

Group 1: Company Performance - China Life reported a net profit of 106.935 billion yuan for 2024, representing a year-on-year increase of 108.9% [3] - China Life's operating revenue for 2024 reached 528.567 billion yuan, up 30.5% compared to the previous year [3] - Aluminum Corporation of China announced a net profit of 12.4 billion yuan for 2024, reflecting an 85.38% year-on-year growth [4] - Broadcom Electric's net profit surged by 411.28% in 2024, with a proposed dividend of 0.70 yuan per 10 shares [10] - China Pacific Insurance's net profit for 2024 increased by 64.9%, with a proposed dividend of 10.8 yuan per 10 shares [10] Group 2: Corporate Actions - Naxin Micro announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance competitiveness and diversify financing channels [7] - Xunji Technology is planning to acquire 100% equity of Shenzhen Jiazhihong Electronics, leading to a significant asset restructuring [5] - Nasda announced the sale of its 100% stake in Lexmark International for an estimated price between 75 million and 150 million USD, significantly lower than the historical investment of 1.385 billion USD [8] - General Shares announced that its controlling shareholder is planning a change in control, leading to a temporary suspension of its stock [9] Group 3: Market Impact - The inclusion of Southwest Design, a subsidiary of Electric Science and Technology, on the U.S. Department of Commerce's Entity List may affect its operations, although the company claims no substantial impact on business [6] - The stock of General Shares will be suspended due to potential changes in control, which may affect investor sentiment [9]

证券代码：603222 证券简称：济民健康 公告编号：2025-005 济民健康管理股份有限公司 关于公司副总裁涉嫌犯罪及公司报案并收到立案通 知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、情况概述 近期，公司陆续收到部分经销商发送的律师函，称除与公司签署《经销协议》 外，还与公司签署了《补充协议》，要求公司按照《补充协议》约定履行退货退 款义务，并支付货款资金占用补偿。公司收到上述律师函后，立即启动了相关事 项调查。 三、预计对公司的影响 何清红女士于 2022 年 2 月加入本公司，任副总裁职务，主要负责预充式导 管冲洗器及安全注射器国内市场的营销工作。销售模式为先款后货，买断式销售， 非货物质量问题概不退货。 2023 年和 2024 年，何清红团队合计实现销售额约 11,719.90 万元。截至目 前，上述销售额中，公司尚未能掌握经销商当前的库存规模，对于经销商尚未实 现终端销售的库存，公司存在被经销商起诉，要求按照《补充协议》退货退款， 并支付资金占用补偿的风险。 何清红及其团队成员上述行为涉嫌伪造 ...

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -15 million and -10 million yuan, a reduction in losses compared to -65.48 million yuan in the same period last year[4]. - The company anticipates a net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, to also be between -15 million and -10 million yuan for 2024[4]. - The expected earnings per share for 2024 is -0.12 yuan[8]. - The company aims to reduce losses in 2024 compared to the previous year's performance[7]. Research and Development - Research and development expenses for 2024 are estimated to be approximately 41.52 million yuan, an increase of 43.67% compared to the same period last year[9]. - The company completed the research and development of new skincare products, including facial masks, essence, and eye cream, which were launched in the fourth quarter of 2024[9]. Operational Impact - The direct property loss from the typhoon disaster affecting the company's subsidiary is estimated at about 30 million yuan, impacting the hospital's operational performance in 2024[9]. - The company did not incur significant impairment provisions in 2024, unlike the previous year where it recorded a total of 79.38 million yuan in impairment provisions[9]. Financial Reporting - The financial data provided is preliminary and has not been audited by registered accountants, with the final figures to be disclosed in the audited annual report[10][11]. - The company emphasizes that there are no significant uncertainties affecting the accuracy of this earnings forecast[10].

证券代码：603222 证券简称：济民健康 公告编号：2025-001 济民健康管理股份有限公司 第五届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况： 济民健康管理股份有限公司（以下简称"公司"）第五届董事会第十六次会议 于 2024 年 12 月 31 日以通讯表决方式召开，会议通知于 2024 年 12 月 28 日通 过电话、邮件及书面形式发出，本次会议由董事李丽莎女士主持，应出席董事 7 名，实际出席董事 7 名。会议的召集，召开符合《公司法》和《公司章程》的有 关规定，会议合法有效。 二、董事会会议审议情况： 经过与会董事认真审议，形成如下决议： 1、以 5 票同意，0 票弃权，0 票反对，2 票回避，审议通过了《关于全资子公 司接受搬迁补偿暨关联交易的议案》。 本议案已经独立董事专门会议审议通过。 2、以 7 票同意，0 票弃权，0 票反对，审议通过了《关于"提质增效重回报" 行动方案的议案》。 上述议案内容详见公司指定信息披露媒体和上海证券交易所网站同日 ...

证券代码：603222 证券简称：济民健康 公告编号：2024-072 济民健康管理股份有限公司 关于通过高新技术企业重新认定的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 本次高新技术企业的认定系公司原证书有效期满后的重新认定。根据《中 华人民共和国企业所得税法》等有关规定，公司自获得高新技术企业认定当年 起三年内（2024 年至 2026 年），可继续享受国家关于高新技术企业的相关优 惠政策，即按 15%的税率计缴企业所得税。 公司 2024 年度已按照 15%的企业所得税税率进行纳税申报及预缴，因此， 本次通过高新技术企业认定不会影响公司 2024 年度的相关财务数据。 特此公告。 济民健康管理股份有限公司董事会 2024 年 12 月 27 日 根据全国高新技术企业认定管理工作领导小组办公室于 2024 年 12 月 26 日 发布的《对浙江省认定机构 2024 年认定报备的高新技术企业进行备案的公告》， 济民健康管理股份有限公司（以下简称"公司"）再次通过高新技术企业重新认 定，证书编号为 GR20243 ...

证券代码：603222 证券简称：济民健康 公告编号：2024-071 济民健康管理股份有限公司 关于全资子公司签署《制造协议》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●合同类型：制造协议 ●合同标的：聚民生物为美国 RTI 公司代工生产安全注射器、安全注射针等 产品。 ●合同生效条件：合同自双方签字之日起生效。 ●合同履行期限：2024 年 12 月至 2034 年 12 月。 ●对上市公司当年业绩的影响：1、锁定双方未来10年继续合作的战略关 系，为聚民生物的长远发展提供了保障；2、为降低因国际市场环境变化而失去 市场份额的风险，双方达成一致将代工产品的价格下调22%左右（每两年对上述 价格进行审查、重新评估及定价）以稳定市场地位；3、上述调价短期将对公司 的利润水平产生不利影响，但有助于稳定市场地位和客户关系，避免因失去市 场份额而带来的更大损失。 ●风险提示：本合同为公司日常生产经营活动相关合同，双方已合作近 20 年，均具有履约能力，但合同履行期限较长，在合同履行过程中，可能存在 ...